Combination of biomarkers of preterm delivery
OwnerCéline MEHATS, Louis MARCELLINinventors
Life of this patent
Estimating the term…
Abstract
The present invention relates to the prognosis and diagnosis of preterm delivery. More specifically, the invention relates to new combination of biomarkers for preterm delivery that enable the accurate prognosis and diagnosis of preterm delivery, and in particular enable the accurate prognosis and diagnosis of preterm delivery before 32 weeks of gestation.
Claims19
A combination of biomarkers comprising COL1A1 and CCN5 for use as biomarkers for preterm delivery, wherein the preterm delivery is a preterm delivery before 32 weeks of gestation.
A method for diagnosing, whether an individual is at risk of preterm delivery and/or imminent birth by determining the presence and/or amount of a combination of biomarkers, wherein the combination of biomarkers comprises COL1A1 and CCN5.
A method for prognosing and/or for diagnosing, whether an individual is at risk of preterm delivery and/or imminent birth, the method comprising:
- a) determining the presence and/or amount of a combination of biomarkers for preterm delivery in a sample obtained from an individual, and
- b) comparing the presence and/or amount of said combination of biomarkers obtained from step b) to the presence and/or amount of said combination of biomarkers in a control sample, to identify an increased risk for preterm delivery, wherein said combination of biomarkers comprises COL1A1 and CCN5.
Dependencies are inferred from the claim text.